Efavirenz (SUSTIVA) expanded access begins October 1.
James
J S
JS
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D006801:Humans; D010078:Oxazines / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz